Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Secures License for an Additional 71 Unique Ovarian Cancer Cell Lines from Ximbio, Cancer Research UK’s Premier Reagents Distributor
Predictive Oncology now has a total of 96 unique Patient Derived Cells (PDCs) from Ovarian Cancer Patients. EAGAN, Minn. , Sept. 22, 2020 (GLOBE NEWSWIRE) -- TumorGenesis, a division of Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”)
View HTML
Toggle Summary Predictive Oncology Inc to Present at LD Micro's "LD 500" Virtual Investor Conference on Wednesday, September 02, 2020 3:40 PM Eastern Time
EAGAN, Minn. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro's "LD 500" Virtual Investor
View HTML
Toggle Summary Soluble Biotech Announces First Contract with a Major Pharmaceutical Company for Protein Expression and Solubility Studies
EAGAN, Minn. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that its Soluble Biotech division, a provider of soluble and stable
View HTML
Toggle Summary Predictive Oncology’s Skyline Medical Sells 8 STREAMWAY® Systems to a Large University Hospital Organization in Virginia; 13 STREAMWAY® Systems Sold Halfway Into Q3 2020
EAGAN, Minn. , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that its Skyline Medical division, producer of the FDA-approved and
View HTML
Toggle Summary Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins, ‘Can We Cure Cancer with Artificial Intelligence?’
LOS ANGELES , Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins , Ph.D., chief innovation officer
View HTML
Toggle Summary Predictive Oncology Reports Second Quarter 2020 Financial Results, Provides Business Update
Increases Readiness for Commercialization with Expanded Portfolio of Solutions for Precision Medicine NEW YORK , Aug. 13, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug
View HTML
Toggle Summary Predictive Oncology Issues Letter to Shareholders
Annual Meeting of Stockholders to be Held on September 3, 2020 NEW YORK , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today issued a letter to
View HTML
Toggle Summary Predictive Oncology Refreshes Board with Appointment of Three New Directors
Adds Industry, Business Development and Financial Expertise NEW YORK , July 14, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of
View HTML
Toggle Summary Predictive Oncology Completes Acquisition of Quantitative Medicine
Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development MINNEAPOLIS , July 07, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug
View HTML
Toggle Summary Predictive Oncology Inc. Announces Receipt of Cash Proceeds of $2.2 Million from Exercise of Warrants
MINNEAPOLIS , June 29, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (the “Company,” “ Predictive Oncology,” “we,” “our” or “us”) (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the
View HTML